Category: Research

The O’Neal Comprehensive Cancer Center at UAB is pleased to announce that the Breast Cancer Resesarch Foundation of Alabama (BCRFA) has generously funded a Pre-R01 grant through the spring cycle of O’Neal Invests.

Birmingham’s Pepper Place has a striking new addition to its teeming farmers’ market and noted food offerings — a multimillion-dollar cancer research laboratory. 

A full course of radiation therapy in milliseconds rather than weeks: That’s the promise of flash therapy.

Alabama is one of three states currently offering an ovarian cancer car tag — and it is changing the future of ovarian cancer research. Since the tag’s inception, proceeds from each ovarian cancer car tag purchased have gone directly to the University of Alabama at Birmingham’s Division of Gynecologic Oncology to support ovarian cancer research.

UAB was well represented at one of the signature oncology conferences this year, ASCO, held in Chicago, Illinois, from May 31–June 4.

Markus Bredel, M.D., Ph.D., is lead author on “Haploinsufficiency of NFKBIA reshapes the epigenome antipodal to the IDH mutation and imparts disease fate in diffuse gliomas” in Cell Reports Medicine (2023). This groundbreaking discovery not only marks a significant milestone in our understanding of diffuse gliomas but also paves the way for improved predictions of disease outcomes and the development of targeted treatment approaches.

The O’Neal Comprehensive Cancer Center at UAB recently awarded six projects a total of $530,000 in research grants through O'Neal Invests. The O’Neal Invests program funds UAB investigators initiating new cancer-related projects to do key, preliminary work in order to enable competitive R01 applications.

The Breast Cancer Research Foundation of Alabama recently awarded eight researchers at the O’Neal Comprehensive Cancer Center at UAB a total of $800,000 in breast cancer research funding.

The Breast Cancer Research Foundation of Alabama recently awarded $320,000 in funding to two researchers at the O'Neal Cancer Center.

A researcher from the University of Alabama at Birmingham School of Engineering has received a $1.4 million, three-year grant to research systemic toxicities in breast cancer. Toxicity is the main dose-limiting factor in cancer treatments. Developing methods to control it could dramatically impact patient health.

The Breast Cancer Research Foundation of Alabama today announced a total investment of $1,275,000 in Alabama-based breast cancer research in 2022.

Though lung cancer remains the leading cause of cancer death in the nation, physicians at the O’Neal Comprehensive Cancer Center at the University of Alabama at Birmingham want patients to know about the advancements in diagnostic technologies and therapies, as well as new screening guidelines, which provide more hope for lung cancer patients than ever before.

New research from University of Alabama at Birmingham researchers is shedding light on racial disparities in breast cancer mortality in women who live in economically deprived neighborhoods.

The University of Alabama at Birmingham Division of Gynecologic Oncology has received $120,000 to further ovarian cancer research from the Norma Livingston Ovarian Cancer Foundation.

The University of Alabama at Birmingham Marnix E. Heersink School of Medicine’s Department of Radiation Oncology researchers have identified potential targets to help overcome therapy-resistant tumors in patients with glioblastoma, the most common and devastating form of primary brain cancer. 

Over the last decade, immune checkpoint blockers, or ICBs, have revolutionized treatment for various advanced cancers, including melanoma, the most aggressive skin cancer that was considered largely incurable not long ago. However, three-fourths of advanced-melanoma patients are resistant to ICBs.

Melanoma is a highly aggressive skin cancer that frequently metastasizes, but current therapies benefit only some patients. Finding new ways to treat melanoma and other cancers is crucial because of the high prevalence of acquired resistance to currently used therapy for treating patients.

New recommendations from the Lancet Commission on COPD, including from Commission Chair Mark Dransfield, M.D., division director of Pulmonary, Allergy and Critical Care Medicine at the University of Alabama at Birmingham, outline ways to eliminate and control COPD worldwide.

Metastatic bladder cancer is generally incurable, so new therapies are an urgent need. Researchers at the University of Alabama at Birmingham now report a potential treatment for a quarter of bladder cancers.

Andres Forero, M.D.A new University of Alabama at Birmingham research study reports that brentuximab vedotin is an effective and safe first course of treatment for older patients with Hodgkin lymphoma that cannot […]

Anindya Dutta, MBBS, Ph.D., and colleagues have described a novel form of gene regulation that is altered in bladder cancer, leading to the boosting of a gene pathway that helps the cancer cells survive during rapid growth.

Looking back on the past 50 years of basic science research at the O'Neal Comprehensive Cancer Center at UAB, cancer scientists reflect on the major discoveries that have paved the way for the future of cancer care.

For more than two decades, University of Alabama at Birmingham researcher Susan Bellis, Ph.D., has studied how the addition of sialic acid to various proteins increases cancer resistance and oncogenicity.

New research from University of Alabama at Birmingham, published in the New England Journal of Medicine, suggests a gene therapy called LentiGlobin could provide a permanent cure for sickle cell disease.